Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Avacta Group Enters Into a Collaboration Agreement with Bruker Corporation

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

January 28, 2021

Avacta Group plc the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation to evaluate the Affimer-based, bead assisted mass spectrometry (“BAMSTM”) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (“Adeptrix”).

Bruker is one of the world’s leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally. It is also one of the foremost suppliers of mass spectrometers with a significant installed based in clinical microbiology laboratories in hospitals worldwide.

Avacta Group has worked with Adeptrix Inc (Beverly, MA, USA) to develop a coronavirus antigen test that combines enrichment of the sample using Affimer® reagents with the analytical power of mass spectrometry. Up to 1,000 samples per day can be analyzed by a single technician using a BAMS assay, exceeding the capacity of the commonly used PCR machines, making BAMS a potentially very attractive high throughput technique for COVID-19 screening in the clinical setting.

Having successfully developed a prototype test with Adeptrix, Avacta has been working with its clinical partners in the UK to refine the assay to fit into the typical workflows in a clinical microbiology laboratory. The collaboration with Bruker announced today will assess the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for SARS-CoV-2 infection to run on Bruker’s MALDI-TOF instruments for sale in the UK and Europe.

Dr. Alastair Smith, Chief Executive Officer of Avacta Group, commented: “I am delighted to have established this collaboration agreement with Bruker to further develop the potential for the BAMS COVID-19 test as a clinical IVD. We will be working closely with Bruker on the clinical assessment of the BAMS assay on Bruker’s MALDI-TOF instruments.”

He concluded, “Our objective is to work with Bruker and our clinical partners to deliver an effective and high throughput assay protocol, that can be applied in the clinical setting, with the required sensitivity and specificity and CE/FDA approvals to provide a useful additional diagnostic tool in the fight against the coronavirus. I look forward to updating the market when we have definitive clinical performance data.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine